Researchers in Vienna are starting a Phase I trial on the first ever vaccine with a potential to treat the neurodegenerative disease.
The Scientist
Most Recent
Much has changed in the 10 years since our first survey of industry researchers. Large companies are now looking to small, nimble ones for services as well as innovation.
The anti-HIV antibodies from mothers carrying HIV could be used to help develop a vaccine.
With 12 new tuberculosis vaccines in clinical development, a plan is needed to introduce the most effective ones throughout the world.
A novel antibody with a powerful affinity for cocaine shows promise in reversing the deadly effects of an overdose.
A vaccine that targets 90 percent of all cancers shows promise in early clinical trials.
One of the researchers who created a highly transmissible form of the bird flu virus has broken his silence and shared which mutations made it possible.
Herd immunity, or the protection of individuals who are not vaccinated due to generally high vaccination rates within a population, does not currently exist in many pockets of the US.
Vaccination via tiny microneedles elicits a powerful immune response in the skin.
Perfluorinated compounds, a class of manufacturing chemicals, may be harming the immune system in a way that reduces the effectiveness of standard childhood vaccines.
Follow The Scientist
Stay Connected with The Scientist
-
The Scientist Magazine
-
The Scientist Careers
-
Neuroscience Research Techniques
-
Genetic Research Techniques
-
Cell Culture Techniques
-
Microbiology and Immunology
-
Cancer Research and Technology
Current Issue
